Case Study: Competitive Treatment Driver Analysis

At MDoutlook, we focus on¬†providing actionable insights to our clients. These insights can provide valuable data¬†to improve market share and compare and contrast our client’s¬†products to those of their competition. Below is a case study outlining the main reasons taxanes are not considered for use following paclitaxel treatment in ovarian cancer.

Customer: Global pharmaceutical company expanding their disease portfolio into new therapeutic areas.

Challenge: Client needed to compare and contrast treatment decision drivers between competitive therapies as input for their clinical development and commercialization planning.

Unique MDoutlook proposition: 

  • Develop comprehensive questionnaire to address both quantitative treatment market share analysis while differentiating qualitative decision driver attributes often retrieved by different research methodologies (e.g. qualitative)
  • Panel Composition:¬†100 screened ovarian cancer treaters
  • Comparative Analysis:
    • By competitive therapies
    • Academic vs. community practice

Value delivered: 

  • Actionable insights to guide patient segmentation, commercial positioning and messaging
  • Robust and projectable quantitative market share analysis
  • Sophisticated qualitative insights generated by a quantitative study methodology that increased the study efficiencies and shortened the study timeline

Send an email to [email protected] to learn more.

july email image